PHAT
Phathom Pharmaceuticals, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
-1.89
P/S
5.10
EV/EBITDA
-15.61
DCF Value
$-6.23
FCF Yield
-18.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
87.1%
Operating Margin
-91.4%
Net Margin
-126.3%
ROE
55.1%
ROA
-85.4%
ROIC
-125.2%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $57.6M | $-21.1M | $-0.29 |
| FY 2025 | $175.1M | $-221.2M | $-3.03 |
| Q3 2025 | $49.5M | $-30.0M | $-0.41 |
| Q2 2025 | $39.5M | $-75.8M | $-1.05 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.61
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.